Regeneron posted a muted top line for 2025—fourth quarter revenue up 3% to $3.9 billion and full-year up 1% to $14.3 billion—powered by surging Dupixent economics while the aflibercept franchise continued to reset. Dupixent global net sales recorded by Sanofi jumped 34% in the quarter to $4.94 billion and 26% for the year to $17.8 billion. In ophthalmology, Eylea HD 8 mg gained traction in the U.S. with fourth quarter sales up 66% to $506 million, yet total U.S. Eylea HD plus Eylea fell 28% to $1.1 billion as legacy erosion outpaced the HD ramp. The FDA cleared Eylea HD for retinal vein occlusion and added monthly dosing flexibility across indications, approved a new vial fill manufacturer, and is reviewing a pre-filled syringe manufacturing addition with a decision expected in the second quarter of 2026. Libtayo secured U.S. and EU approvals as the first adjuvant immunotherapy for high-risk cutaneous squamous cell carcinoma, and the EU approved Dupixent in chronic spontaneous urticaria.
The strategic question is whether label breadth and manufacturing redundancy can overcome a structurally tougher retina market. Regeneron is now defending aflibercept on two fronts: premium efficacy and interval claims versus fast-growing Vabysmo, and a value front against compounded bevacizumab as patient affordability pushes off-label use. The company’s own disclosure that U.S. Eylea volumes are pressured by payers and price underscores a shift from a clinical differentiation battle to an access and adherence game. Monthly dosing optionality and pre-filled syringe convenience will help in clinic flow and switching, but sustained share defense may hinge on copay support models and payer contracting as much as on efficacy deltas.
For payers and retina specialists, the near-term calculus is practical: do new labels and supply de-risking justify maintaining higher-cost biologics in cost-constrained clinics. The addition of a second fill/finish site and a pending pre-filled syringe supply expansion aim to avoid prior bottlenecks that can disrupt loading schedules and drive involuntary switches. Patient impact will turn on consistency of supply, affordability programs, and whether extended-interval regimens translate into real-world reductions in visit burden without compromising outcomes.
Medical Affairs teams face a parallel opportunity and challenge outside ophthalmology. Libtayo’s entry into the adjuvant CSCC setting opens a new standard-of-care conversation in perioperative pathways, requiring rapid education of surgeons, radiation oncologists, and dermatologic oncologists, plus real-world evidence to support recurrence-risk stratification and duration. Dupixent’s growth into CSU and a potential allergic fungal rhinosinusitis label puts allergists and ENT specialists at the center of uptake, with payer evidence needs around step therapy and quality-of-life gains likely to drive access decisions.
Regeneron is also recoding its growth algorithm toward diversified platforms. A 2026 R&D ramp signals intent: launching a GLP-1/GIP program in obesity (olatorepatide) and pairing it with Praluent to test a cardiometabolic bundle; advancing complement combinations in PNH and geographic atrophy; pushing factor XI antibodies in anticoagulation; and moving into genetic medicines, with an FDA decision pending for DB-OTO in pediatric hearing loss and a Tessera collaboration in alpha-1 antitrypsin deficiency. A planned $2 billion U.S. manufacturing build-out complements $3.5 billion in 2025 buybacks and a newly declared dividend, balancing pipeline spend with shareholder returns.
The next 12 months are executional: an FDA decision on the Eylea HD pre-filled syringe, pivotal readouts for the LAG-3 plus PD-1 regimen versus pembrolizumab in melanoma, potential first-in-class approvals in rare disease and gene therapy, and the kickoff of an obesity franchise. The central test is whether Regeneron can convert breadth into durable, multi-franchise revenue—reducing reliance on Dupixent while stabilizing ophthalmology—before payer pressure and next-wave competitors reset the terms of engagement.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
